Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|96|2|182-191

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.2, 2014-08, pp. : 182-191

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 8-9

Karger

Access to resources Recommend Favorite

Population pharmacokinetics of erlotinib in Japanese patients with advanced non‐small cell lung cancer

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 2, 2015-04 ,pp. : 232-239

John Wiley & Sons Inc

Access to resources Recommend Favorite

A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non–small cell lung cancer (NSCLC)

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : 1321-1327

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 82, Iss. 1, 2012-01 ,pp. : 25-29

Karger

Access to resources Recommend Favorite